Gonzalez JM, Johnson FR, Runken MC, Poulos CM. Evaluating migraineurs' preferences for migraine treatment outcomes using a choice experiment. Headache. 2013 Nov;53(10):1635-50.
Bhattacharyya S, Sacco P, Shirore R, Sonathi V, Thomas SK. A de novo economic model to assess the cost and quality of life consequences of an intervention for levodopa induced dyskinesia amongst patients with Parkinson's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A590-1.
Rouse M, McKenna S, Twiss J, Graham JE, Wilburn J. Quality of life outcomes in multiple sclerosis: a review of the literature. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A626. doi: 10.1016/j.jval.2013.08.1843
Casas L, Torrent M, Zock JP, Doekes G, Forns J, Guxens M, Taubel M, Heinrich J, Sunyer J. Early life exposures to home dampness, pet ownership and farm animal contact and neuropsychological development in 4 year old children: a prospective birth cohort study. Int J Hyg Environ Health. 2013 Nov;216(6):690-7. doi: 10.1016/j.ijheh.2012.12.013
Luciano JV, Aguado J, Serrano-Blanco A, Calandre EP, Rodriguez-Lopez CM. Dimensionality, reliability, and validity of the revised fibromyalgia impact questionnaire in two Spanish samples. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1682-9.
López-León S, Rivero E. Statins for prevention of alzheimer's disease: systematic review and meta-analysis. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal, Spain.
Marcano Belisario J, Tudor KI, Sumalinog ARN, Middleton LT, Car J. Educational interventions for improving the skills of medical practitioners to detect, diagnose, and manage people with cognitive impairment and dementia (Protocol). Cochrane Database Syst Rev. 2013 Jun 6. doi: 10.1002/14651858.CD010580
Davis KL, Fitzgerald T, Meyers J, Kulkarni A, Svarvar P, Hewitt D. Incidence of adverse treatment effects in parkinson's disease: evidence from a large employer population. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 15, 2013. [abstract] Value Health. 2013 May; 16(3):A100.
Davis KL, Fitzgerald T, Kulkarni A, Meyers J, Svarvar P, Hewitt D. Comparative risk of adverse treatment effects in parkinson's disease: evidence from a large employer population. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 15, 2013. [abstract] Value Health. 2013 May; 16(3):A100.
Davis KL, Fitzgerald TP, Meyers J, Kulkarni A, Svarvar P, Hewitt DJ. Economic burden of adverse treatment effects in parkinson's disease: evidence from a large employer population. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A103-4.
Gnanasakthy A, DeMuro-Mercon CJ, Clark MJ, Mordin MM, Thomas S. Role of patient-reported outcome measures in the assessment of central nervous system agents. Ther Innov Regul Sci. 2013;47(5):613-8.